Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Executes the first project for developing and manufacturing a novel anticancer mAb
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Subscribe To Our Newsletter & Stay Updated